OBJECTIVES:Varenicline (2 mg/d) has been shown to be efficacious in reducing alcohol consumption. A lower dose of varenicline may be effective in reducing alcohol use while minimizing the potential for side effects. METHODS: This double-blind, placebo-controlled investigation examined the effect of varenicline (0, 1, 2 mg/d) on alcohol consumption in nontreatment-seeking adults meeting the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) criteria for alcohol use disorders (N = 60). Following 7 days of medication pretreatment, participants were administered a low fixed dose of alcohol (0.3 g/dL), and subjective and physiologic responses were assessed. A 2-hour ad libitum alcohol self-administration period followed. We also explored relationships between plasma varenicline levels and consumption. RESULTS:Overall, frequency and severity of adverse events were minimal. The 1 mg/d dose reduced the frequency of insomnia compared with the 2 mg/d dose. The 2 mg/d varenicline dose versus placebo reduced alcohol craving and showed limited effect on reduced alcohol consumption. Alcohol craving and consumption did not differ between the 1 mg/d varenicline dose versus placebo. Trough varenicline plasma levels greater than or equal to 3 ng/mL were associated with reduced drinking and levels greater than or equal to 5 ng/mL were associated with reduced heavy drinking. CONCLUSIONS: Overall, we found no evidence supporting an effect of 1 mg/d varenicline on craving or consumption, suggesting that doses of varenicline less than 2 mg/d may not be effective in reducing alcohol-related outcomes. Importantly, results suggest that higher plasma levels of varenicline may be needed to maximize the effect of varenicline on alcohol consumption and should be investigated in drinkers meeting criteria for alcohol use disorders.
RCT Entities:
OBJECTIVES:Varenicline (2 mg/d) has been shown to be efficacious in reducing alcohol consumption. A lower dose of varenicline may be effective in reducing alcohol use while minimizing the potential for side effects. METHODS: This double-blind, placebo-controlled investigation examined the effect of varenicline (0, 1, 2 mg/d) on alcohol consumption in nontreatment-seeking adults meeting the Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) criteria for alcohol use disorders (N = 60). Following 7 days of medication pretreatment, participants were administered a low fixed dose of alcohol (0.3 g/dL), and subjective and physiologic responses were assessed. A 2-hour ad libitum alcohol self-administration period followed. We also explored relationships between plasma varenicline levels and consumption. RESULTS: Overall, frequency and severity of adverse events were minimal. The 1 mg/d dose reduced the frequency of insomnia compared with the 2 mg/d dose. The 2 mg/d varenicline dose versus placebo reduced alcohol craving and showed limited effect on reduced alcohol consumption. Alcohol craving and consumption did not differ between the 1 mg/d varenicline dose versus placebo. Trough varenicline plasma levels greater than or equal to 3 ng/mL were associated with reduced drinking and levels greater than or equal to 5 ng/mL were associated with reduced heavy drinking. CONCLUSIONS: Overall, we found no evidence supporting an effect of 1 mg/d varenicline on craving or consumption, suggesting that doses of varenicline less than 2 mg/d may not be effective in reducing alcohol-related outcomes. Importantly, results suggest that higher plasma levels of varenicline may be needed to maximize the effect of varenicline on alcohol consumption and should be investigated in drinkers meeting criteria for alcohol use disorders.
Authors: Hélène M Faessel; R Scott Obach; Hans Rollema; Patanjali Ravva; Kathryn E Williams; Aaron H Burstein Journal: Clin Pharmacokinet Date: 2010-12 Impact factor: 6.447
Authors: Hélène M Faessel; Megan A Gibbs; David J Clark; Kevin Rohrbacher; Marilyn Stolar; Aaron H Burstein Journal: J Clin Pharmacol Date: 2006-12 Impact factor: 3.126
Authors: Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks Journal: Biochem Pharmacol Date: 2007-07-27 Impact factor: 5.858
Authors: Sherry A McKee; Emily L R Harrison; Stephanie S O'Malley; Suchitra Krishnan-Sarin; Julia Shi; Jeanette M Tetrault; Marina R Picciotto; Ismene L Petrakis; Naralys Estevez; Erika Balchunas Journal: Biol Psychiatry Date: 2009-02-27 Impact factor: 13.382
Authors: Jelte A Wouda; Danai Riga; Wendy De Vries; Mathijs Stegeman; Yvar van Mourik; Dustin Schetters; Anton N M Schoffelmeer; Tommy Pattij; Taco J De Vries Journal: Psychopharmacology (Berl) Date: 2011-02-18 Impact factor: 4.530
Authors: Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith Journal: Alcohol Clin Exp Res Date: 2017-07-10 Impact factor: 3.455
Authors: Terril L Verplaetse; Brian P Pittman; Julia M Shi; Jeanette M Tetrault; Sabrina Coppola; Sherry A McKee Journal: Alcohol Clin Exp Res Date: 2016-06-01 Impact factor: 3.455
Authors: Jingyi Wang; Angelo Blasio; Holly L Chapman; Christelle Doebelin; Victor Liaw; Alexander Kuryatov; Simone M Giovanetti; Jon Lindstrom; Li Lin; Michael D Cameron; Theodore M Kamenecka; Matthew B Pomrenze; Robert O Messing Journal: Neuropsychopharmacology Date: 2019-08-08 Impact factor: 7.853
Authors: Walter Roberts; Terril L Verplaetse; Kelly Moore; Lindsay Oberleitner; Marina R Picciotto; Sherry A McKee Journal: J Psychopharmacol Date: 2017-03-29 Impact factor: 4.153
Authors: Terril L Verplaetse; Walter Roberts; Kelly E Moore; MacKenzie R Peltier; Lindsay M Oberleitner; Sherry A McKee Journal: J Clin Psychopharmacol Date: 2019 Mar/Apr Impact factor: 3.153
Authors: Sarah E Maggio; Meredith A Saunders; Thomas A Baxter; Kimberly Nixon; Mark A Prendergast; Guangrong Zheng; Peter Crooks; Linda P Dwoskin; Rachel D Slack; Amy H Newman; Richard L Bell; Michael T Bardo Journal: Psychopharmacology (Berl) Date: 2018-02-18 Impact factor: 4.530